GL Pharm Tech
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
GL Pharm Tech makes and markets prescription and over-the-counter medicines, including treatments for nerve pain, stomach ulcers, inflammation, and hormonal conditions such as contraceptives, supplied to hospitals, pharmacies, and other healthcare buyers in Korea.
Listed on KOSDAQ, Korea's tech and small-cap exchange, the company operates across two main activities: distributing finished medicines under its own marketing arm and manufacturing them through its consolidated subsidiary, GL Pharma. A meaningful share of its revenue comes from licensing its improved-drug formulations to domestic and overseas pharmaceutical companies and collecting ongoing royalties on their sales.
Summary is AI-generated and may contain errors · figures from DART filings
GL Pharm Tech's consolidated subsidiary, GL Pharma, handles the manufacturing side of the business, while the parent focuses on research-and-development services and sales marketing.
GL Pharm Tech in five facts
What does GL Pharm Tech do?
GL Pharm Tech makes and markets prescription and over-the-counter medicines, including treatments for nerve pain, stomach ulcers, inflammation, and hormonal conditions such as contraceptives, supplied to hospitals, pharmacies, and other healthcare buyers in Korea.
Where is GL Pharm Tech listed and in which sector?
GL Pharm Tech (Korean name: 지엘팜텍) trades under KRX code 204840 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Consumer Staples sector, Staples Retail.
How large is GL Pharm Tech?
Its market capitalisation was US$44.8M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were GL Pharm Tech's latest annual revenue and operating profit?
For fiscal year 2025, GL Pharm Tech reported revenue of US$26.6M, operating profit of US$202.6K and net income of US$9.4K, per its annual report on DART (data retrieved from DART on 2026-09-17). Revenue was up 35.4% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-17
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- [Amended] Supply contract signed
GL Pharm Tech updated a previously disclosed supply contract with Okura Bioscience Co., Ltd., now worth US$728K, about 16.1% of its recent annual revenue, running through Sep 2026.
Supply contract · Sep 21 - Completion report on merger, etc. (merger)
GL Pharm Tech Co., Ltd. completed its small-scale merger with its wholly owned subsidiary GL Pharma Co., Ltd. on July 31, 2026, at a no-capital-increase merger ratio of 1.0000000:0.0000000 with no new shares issued; 149 dissenting shareholders holding 909,466 shares (1.17% of outstanding shares) submitted objection notices, but no appraisal rights were granted.
M&A · Jul 31 - Trading suspension (share consolidation/split registration)
KOSDAQ trading in GL Pharm Tech common shares will be suspended from July 20, 2026 until the day before the share-consolidation re-listing date, due to a change in electronic registration from a share consolidation.
M&A · Jul 14 - [Attachment amended] Material event report (merger)M&A · Jun 1
- [Attachment amended] Material event report (merger)M&A · May 28
- Material event report (merger)M&A · May 28
- Change of 30% or more in revenue or profit/loss structure (15% for large companies)
GL Pharm Tech reported consolidated results for FY2025: revenue of US$24.1M (+35.4% year on year), operating profit of US$179K (from a loss a year earlier) and a net loss of US$127K.
Earnings · Feb 9